Sr. Director, Treasury at Legend Biotech

Franklin Township, New Jersey, United States

Legend Biotech Logo
Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
BiotechnologyIndustries

Requirements

  • Bachelor's degree in Finance, Accounting, or related field; MBA or CFA preferred
  • 10+ years of progressive treasury experience, including leadership roles in a public company
  • Ability to work independently and collaboratively, as required, in a fast-paced, matrixed, team environment consisting of internal and external team members across different time zones
  • Excellent analytical, communication, and leadership skills
  • Strength in communicating and working independently and effectively with broad stakeholders
  • Process-oriented with strong analytical skills for risk identification and management
  • Adept in Excel
  • Strong knowledge of global cash management, capital markets, and treasury systems
  • Experience in biotech, pharma, or high-growth industries is a plus

Responsibilities

  • Overseeing and managing global Treasury activities
  • Maintaining US, EU, and China banking relationships, including meeting with them at least once annually; ensuring the number of banking institutions utilized are adequate based upon risk and business requirements and not excessive; managing the overall banking fees
  • Implementing and maintaining cash forecast model for operating entities and managing the investment strategy to maximize interest in risk-averse investments, along with maintaining the principle in secured banks and investments
  • Overseeing cash & liquidity management; developing and executing treasury strategies aligned with corporate objectives
  • Identifying, assisting in preparation, and maintaining the capital infusion and intercompany loans documentation required to fund the different operating entities; working closely with in-house and external Legal counsel and Treasury in China (Legend Ireland will serve as the Treasury center)
  • Analyzing and determining when hedging will be required as Legend’s investment in EU operations grows, and implementing a process to hedge once required
  • Managing the global credit card program
  • Authorizing contract spend and signing statement of work based upon functional leaders’ approval as well as guidance from the legal entity Board; supporting US legal entity board meetings
  • Providing ad hoc analysis as required
  • Accountable for FP&A BCMA and Legend Business Units in US and EU

Skills

Treasury Management
Cash Forecasting
Liquidity Management
Investment Strategy
Banking Relationships
Risk Management
Cash Management

Legend Biotech

Develops and commercializes cell therapies

About Legend Biotech

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Franklin Township, New JerseyHeadquarters
2014Year Founded
$146.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Sick Leave
Paid Holidays
Remote Work Options

Risks

Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.
Collaboration with Multiply Labs may face technological challenges, delaying production timelines.
Financial strain from new R&D facility could affect operational focus if advancements lag.

Differentiation

Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
The company is technology agnostic, exploring multiple platforms for effective cancer treatments.
Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.

Upsides

Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.
New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.
Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.

Land your dream remote job 3x faster with AI